Market Overview

UPDATE: Piper Jaffray Downgrades Biogen Idec to Neutral on Valuation

Share:
Related BIIB
Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold
Wall Street's M&A Chatter From June 21: Staples-Sycamore Partners, Diageo-Casamigos, Bristol-Myers, Acadia Pharma
Too Late To Catch Biotech Rally As Trump Fears Subside? (Investor's Business Daily)

Piper Jaffray reduced its rating on Biogen Idec (NASDAQ: BIIB) from Overweight to Neutral and lowered its price target from $175 to $166.

Piper Jaffray commented, "We are downgrading BIIB to Neutral from Overweight based on valuation as we believe expectations are high for the upcoming BG-12 launch and fairly reflected in shares given its premium P/E multiple (21x 2013) versus the large cap group average (16x). We believe this level of premium will be difficult to maintain unless Phase III dexpramipexole ALS data (early 2013) supports regulatory approval. As a result, we are reducing our price target to $166 from $175 as we assume a lower multiple (18x vs. 19x previously) on our 2014 EPS estimates."

Biogen Idec closed at $150.00 on Wednesday.

Latest Ratings for BIIB

DateFirmActionFromTo
Jun 2017Deutsche BankInitiates Coverage OnBuy
Jun 2017UBSUpgradesSellNeutral
Mar 2017Leerink SwannDowngradesOutperformMarket Perform

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (BIIB)

View Comments and Join the Discussion!